Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 3, 2007, Pages 846-854

  Zhao, Y ^a   Valdez, G R ^b   Fekete, E M ^a,c   Rivier, J E ^d   Vale, W W ^d   Rice, K C ^e   Weiss, F ^a   Zorrilla, Eric P ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b GRAND VALLEY STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PÉCS   (Hungary)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 (4 BROMO 2 CHLOROPHENYL) N,N BIS(2 METHOXYETHYL) 2,7 DIMETHYLPYRAZOLO[1,5 A] 1,3,5 TRIAZIN 4 AMINE 9 CHLORIDE; ANGIOTENSIN II; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; HORMONE RECEPTOR STIMULATING AGENT; MJL 11092; PYRAZOLE DERIVATIVE; RECEPTOR SUBTYPE; STRESSING 1 A; UNCLASSIFIED DRUG; UROCORTIN III;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; COPING BEHAVIOR; DEFENSIVE BEHAVIOR; DRUG SELECTIVITY; FREEZING; GROOMING; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REARING; SEPTUM PELLUCIDUM; SOCIAL INTERACTION;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CORTICOTROPIN-RELEASING HORMONE; INJECTIONS, INTRAVENTRICULAR; MALE; PEPTIDES, CYCLIC; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SOCIAL BEHAVIOR; TRIAZINES; UROCORTINS;

EID: 36348935684     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.123208     Document Type: Article

References (42)

1. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, and Lee KF (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24:410-414.
2. Bale TL and Vale WW (2004) CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44:525-557.
3. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR, et al. (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24:403-409.
4. De Boer SF and Koolhaas JM (2003) Defensive burying in rodents: ethology, neurobiology and psychopharmacology. Eur J Pharmacol 463:145-161.
5. Diamant M, Kashtanov SI, Fodor M, and de Wied D (1992) Corticotropin-releasing factor induces differential behavioral and cardiovascular effects after intracerebroventricular and lateral hypothalamic/perifornical injections in rats. Neuroendocrinology 56:750-760.
6. Elkabir DR, Wyatt ME, Vellucci SV, and Herbert J (1990) The effects of separate or combined infusions of corticotrophin-releasing factor and vasopressin either intraventricularly or into the amygdala on aggressive and investigative behaviour in the rat. Regul Pept 28:199-214.
7. Farrokhi C, Blanchard DC, Griebel G, Yang M, Gonzales C, Markham C, and Blanchard RJ (2004) Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters. Pharmacol Biochem Behav 77:465-469.
8. Fekete EM and Zorrilla EP (2007) Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 28:1-27.
9. File SE and Seth P (2003) A review of 25 years of the social interaction test. Eur J Pharmacol 463:35-53.
10. Gammie SC, Hasen NS, Stevenson SA, Bale TL, and D'Anna KL (2005) Elevated stress sensitivity in corticotropin-releasing factor receptor 2 deficient mice decreases maternal, but not intermale aggression. Behav Brain Res 160:169-177.
11. Gehlert DR, Shekhar A, Morin SM, Hipskind PA, Zink C, Gackenheimer SL, Shaw J, Fitz SD, and Sajdyk TJ (2005) Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor. Eur J Pharmacol 509:145-153.
12. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, et al. (2000) Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci U S A 97:6079-6084.
13. Hammack SE, Pepin JL, DesMarteau JS, Watkins LR, and Maier SF (2003) Low doses of corticotropin-releasing hormone injected into the dorsal raphe nucleus block the behavioral consequences of uncontrollable stress. Behav Brain Res 147:55-64.
14. Henry B, Vale W, and Markou A (2006) The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci 26:9142-9152.
15. Hoare SR, Sullivan SK, Fan J, Khongsaly K, and Grigoriadis DE (2005) Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity. Peptides 26:457-470.
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
17. Jagoda E, Contoreggi C, Lee MJ, Kao CH, Szajek LP, Listwak S, Gold P, Chrousos G, Greiner E, Kim BM, et al. (2003) Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2. J Med Chem 46:3559-3562.
18. Jasnow AM, Davis M, and Huhman KL (2004) Involvement of central amygdalar and bed nucleus of the stria terminalis corticotropin-releasing factor in behavioral responses to social defeat. Behav Neurosci 118:1052-1061.
19. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG, and Spiess J (2000) Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24:415-419.
20. Liu J, Yu B, Neugebauer V, Grigoriadis DE, Rivier J, Vale WW, Shinnick-Gallagher P, and Gallagher JP (2004) Corticotropin-releasing factor and Urocortin I modulate excitatory glutamatergic synaptic transmission. J Neurosci 24:4020-4029.
21. McGinnis MY, Lumia AR, Breuer ME, and Possidente B (2002) Physical provocation potentiates aggression in male rats receiving anabolic androgenic steroids. Horm Behav 41:101-110.
22. Mele A, Cabib S, Oliverio A, Melchiorri P, and Puglisi-Allegra S (1987) Effects of corticotropin releasing factor and sauvagine on social behavior of isolated mice. Peptides 8:935-938.
23. Ohata H and Shibasaki T (2004) Effects of urocortin 2 and 3 on motor activity and food intake in rats. Peptides 25:1703-1709.
24. Pellegrino LJ, Pellegrino AS, and Cushman AJ (1979) A Stereotaxic Atlas of the Rat Brain, Plenum Press, New York.
25. Pelleymounter MA, Joppa M, Ling N, and Foster AC (2002) Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther 302:145-152.
26. Pelleymounter MA, Joppa M, Ling N, and Foster AC (2004) Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25:659-666.
27. Pesold C and Treit D (1992) Excitotoxic lesions of the septum produce anxiolytic effects in the elevated plus-maze and the shock-probe burying tests. Physiol Behav 52:37-47.
28. Risbrough VB, Hauger RL, Pelleymounter MA, and Geyer MA (2003) Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) 170:178-187.
29. Risbrough VB, Hauger RL, Roberts AL, Vale WW, and Geyer MA (2004) Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci 24:6545-6552.
30. Rivier J, Gulyas J, Kunitake K, DiGruccio M, Cantle JP, Perrin MH, Donaldson C, Vaughan J, Million M, Gourcerol G, et al. (2007) Stressin1-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist. J Med Chem 50:1668-1674.
31. Robison CL, Meyerhoff JL, Saviolakis GA, Chen WK, Rice KC, and Lumley LA (2004) A CRH1 antagonist into the amygdala of mice prevents defeat-induced defensive behavior. Ann NY Acad Sci 1032:324-327.
32. Rosner B (1995) Fundamentals of Biostatics, Duxbury Press, Boston, MA.
33. Rühmann A, Bonk I, and Kopke AK (1999) High-affinity binding of urocortin and astressin but not CRF to G protein-uncoupled CRFR1. Peptides 20:1311-1319.
34. Takahashi LK, Ho SP, Livanov V, Graciani N, and Arneric SP (2001) Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902:135-142.
35. Takahashi LK, Kalin NH, and Baker EW (1990) Corticotropin-releasing factor antagonist attenuates defensive-withdrawal behavior elicited by odors of stressed conspecifics. Behav Neurosci 104:386-389.
36. Tazi A, Dantzer R, Le Moal M, Rivier J, Vale W, and Koob GF (1987) Corticotropin-releasing factor antagonist blocks stress-induced fighting in rats. Regul Pept 18:37-42.
37. Valdez GR, Inoue K, Koob GF, Rivier J, Vale W, and Zorrilla EP (2002) Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res 943:142-150.
38. Valdez GR, Sabino V, and Koob GF (2004) Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. Alcohol Clin Exp Res 28:865-872.
39. Valdez GR, Zorrilla EP, Rivier J, Vale WW, and Koob GF (2003) Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res 980:206-212.
40. Venihaki M, Sakihara S, Subramanian S, Dikkes P, Weninger SC, Liapakis G, Graf T, and Majzoub JA (2004) Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. J Neuroendocrinol 16:411-422.
41. Zorrilla EP and Koob GF (2004) The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 13:799-828.
42. Zorrilla EP, Reinhardt LE, Valdez GR, Inoue K, Rivier JE, Vale WW, and Koob GF (2004) Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity. J Pharmacol Exp Ther 310:1027-1034.